TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30060100

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 30
Study: 28159118

Group type: EXPERIMENTAL
Intervention: Midwife-led psycho-education intervention for childbirth fear
Number of subjects: 339

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 339
Study: 25363863

Group type: EXPERIMENTAL
Intervention: Exposure to temptation with self-regulation endorsement for four consecutive days.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulated temptation strength in addition to exposure to temptation.
Number of subjects: 0
Study: 23866813

Group type: EXPERIMENTAL
Intervention: Lyprinol/Omega XL (PCSO-524)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 21929600

Group type: EXPERIMENTAL
Intervention: Continuous sublingual immunotherapy (SLIT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Coseasonal sublingual immunotherapy (SLIT)
Number of subjects: 80
Study: 19673328

Group type: EXPERIMENTAL
Intervention: Self-formulated Xingchang Decoction (XCD)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Mosapride (control)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: XCD
Number of subjects: 118
Study: 16721465

Group type: EXPERIMENTAL
Intervention: Delton sealant
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Filtek Flow sealant
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Dyract Flow sealant
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Vitremer sealant
Number of subjects: 56
Study: 15706659

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg OW
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Risedronate 35 mg OW
Number of subjects: 1053
Study: 11714186

Group type: EXPERIMENTAL
Intervention: Telephone and mail interventions for higher intensity exercise
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Telephone and mail interventions for lower intensity exercise
Number of subjects: 140

Group type: COMPARATOR
Intervention: Predominantly mail for higher intensity exercise
Number of subjects: 140

Group type: COMPARATOR
Intervention: Telephone and mail for lower intensity exercise
Number of subjects: 140
Study: 9129791

Group type: EXPERIMENTAL
Intervention: Nonpathogenic Escherichia coli strain Nissle 1917 (E. coli DSM 6601, Mutaflor)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo suspension (1 ml of phosphate‐buffered saline)
Number of subjects: 27
Study: 8912742

Group type: EXPERIMENTAL
Intervention: Maneuver 1 (rapid inspiration without an end‐inspiratory pause)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Maneuver 2 (slow inspiration with an end‐inspiratory pause of approximately 5 s)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Salbutamol administration
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Breathing air and after equilibration with 80% helium in oxygen
Number of subjects: 41
Study: 2273683

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7008048

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31783907

Group type: EXPERIMENTAL
Intervention: Nintendo Wii™Fit for 30 min/day for 8 weeks
Number of subjects: 36
Study: 26939828

Group type: EXPERIMENTAL
Intervention: Bioptron light therapy + cryotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 50
Study: 25194951

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 24656950

Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 17
Study: 22745657

Group type: EXPERIMENTAL
Intervention: Social-skills training plus parental training
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 56
Study: 20422289

Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) prevention program
Number of subjects: 4407
Study: 17594260

Group type: EXPERIMENTAL
Intervention: VRET
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: VRET plus coping self‐statements
Number of subjects: 26
Study: 15802770

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estrogen
Number of subjects: 0
Study: 11935507

Group type: EXPERIMENTAL
Intervention: Composite fiber-reinforced dowels (1.00 mm diameter) luted with BIS-GMA resin bonding system
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Composite fiber-reinforced dowels (1.25 mm diameter) luted with BIS-GMA resin bonding system
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Composite fiber-reinforced dowels (1.50 mm diameter) luted with BIS-GMA resin bonding system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stainless steel dowels (1.25 mm diameter) luted with zinc phosphate cement
Number of subjects: 40
Study: 11692349

Group type: EXPERIMENTAL
Intervention: 5% lidocaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 20% benzocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (lidocaine-tasting)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (benzocaine-tasting)
Number of subjects: 20
Study: 8784330

Group type: EXPERIMENTAL
Intervention: Home-based, parent-child autotutorial program (PCAT group)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Face-to-face counseling session with a registered dietitian (counseling group)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 303
Study: 1628636

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study: 6467772

Group type: EXPERIMENTAL
Intervention: Parents received three letters stressing the value of continuous pediatric care
Number of subjects: 445

Group type: COMPARATOR
Intervention: Control group (no letters received)
Number of subjects: 445
Study: 31209191

Group type: EXPERIMENTAL
Intervention: Oral Na/K citrate plus saline infusion (treatment group)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Oral water plus saline infusion (placebo group)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: CIN-positive patients in treatment group
Number of subjects: 201
Study: 27889832

Group type: EXPERIMENTAL
Intervention: Selumetinib 25 mg co-administered with itraconazole 200 mg twice daily (study A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Selumetinib 25 mg co-administered with fluconazole 400 mg on day 1 then 200 mg/day (study A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Selumetinib 75 mg co-administered with rifampicin 600 mg/day (study B)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Selumetinib 25 mg alone (study A)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Selumetinib 75 mg alone (study B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Selumetinib co-administered with itraconazole (study A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Selumetinib co-administered with rifampicin (study B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Selumetinib co-administered with fluconazole (study A)
Number of subjects: 48
Study: 25971244

Group type: EXPERIMENTAL
Intervention: PDSAFE (physiotherapist delivered, individually tailored and progressive, home-based programme)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 600
Study: 23656463

Group type: EXPERIMENTAL
Intervention: Soy supplement diet (Soy Group, SG; n = 72)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Casein supplement diet (Casein Group, CG; n = 68)
Number of subjects: 140
Study: 21895613

Group type: EXPERIMENTAL
Intervention: Pelvicol
Number of subjects: 132

Group type: COMPARATOR
Intervention: Conventional colporrhaphy
Number of subjects: 132
Study: 19622007

Group type: EXPERIMENTAL
Intervention: Metformin + colesevelam HCl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colesevelam HCl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin + matching placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17597499

Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum extract (2 grams, twice daily for 10 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum extract
Number of subjects: 16
Study: 15080351

Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine solution applied 3 times at 2-month intervals (N = 13)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No treatment (Control group, N = 12)
Number of subjects: 25
Study: 11159263

Group type: EXPERIMENTAL
Intervention: Sameridine 0.73 mg/kg (S-Large)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sameridine 0.15 mg/kg (S-Small)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Morphine 0.10 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8483018

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Long-acting isosorbide dinitrate
Number of subjects: 278

Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 278

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 278
Study: 3710663

Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g daily for 3 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29413502

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 125 mg subcutaneously (SC)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg orally
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo SC
Number of subjects: 310
Study: 26771423

Group type: EXPERIMENTAL
Intervention: Calcium Carbonate (500 mg/d)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Calcium Phosphate (500 mg/d)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 27

Group type: COMPARATOR
Intervention: Washout
Number of subjects: 27
Study: 24829497

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM)
Number of subjects: 15

Group type: COMPARATOR
Intervention: BP education (control intervention)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Controlled breathing (CB)
Number of subjects: 15
Study: 23842679

Group type: EXPERIMENTAL
Intervention: Endurance training (without weight loss)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endurance training + weight loss
Number of subjects: 0
Study: 20592121

Group type: EXPERIMENTAL
Intervention: Facial skin stretch using a robotic device applied lateral to the side of the mouth before movement initiation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control tests without facial skin stretch.
Number of subjects: 0
Study: 17922130

Group type: EXPERIMENTAL
Intervention: Triadcortyl (TAC) ointment
Number of subjects: 64

Group type: COMPARATOR
Intervention: 10% glycerine-ichthammol (GI) solution
Number of subjects: 64
Study: 16626752

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 12773333

Group type: EXPERIMENTAL
Intervention: Servoventilator breathing
Number of subjects: 7

Group type: COMPARATOR
Intervention: Spontaneous breathing
Number of subjects: 7
Study: 11063474

Group type: EXPERIMENTAL
Intervention: Intervention children
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control children
Number of subjects: 540
Study: 8669572

Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope
Number of subjects: 167

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 167
Study: 1732266

Group type: EXPERIMENTAL
Intervention: Unilateral total hip replacement
Number of subjects: 72

Group type: COMPARATOR
Intervention: Bilateral total hip replacement
Number of subjects: 72
Study: 3113778

Group type: EXPERIMENTAL
Intervention: TRH infusion (5 micrograms/min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: D-Ala2-MePhe4-met-enkephalin-0-ol (DAMME) bolus (250 micrograms)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: D-Ala2-MePhe4-met-enkephalin-0-ol (DAMME) bolus (250 micrograms) after TRH infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline infusion with DAMME bolus
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: TRH infusion alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: TRH infusion with DAMME bolus
Number of subjects: 6
Study: 31713994

Group type: EXPERIMENTAL
Intervention: Major abdominal surgery (one surgery)
Number of subjects: 10481

Group type: EXPERIMENTAL
Intervention: Major abdominal surgery (two or more surgeries)
Number of subjects: 10481

Group type: EXPERIMENTAL
Intervention: Multiple surgeries
Number of subjects: 10481

Group type: EXPERIMENTAL
Intervention: Stoma formation among surgical patients
Number of subjects: 10481

Group type: EXPERIMENTAL
Intervention: New ostomates
Number of subjects: 10481

Group type: COMPARATOR
Intervention: Nonsurgical controls
Number of subjects: 10481
Study: 28605158

Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study: 26426277

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 24405341

Group type: EXPERIMENTAL
Intervention: High-stress simulated scenario
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control simulated scenario
Number of subjects: 54
Study: 22515556

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose, 90 mg twice daily maintenance dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AR-C124910XX (active metabolite)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticagrelor (after 2 weeks of clopidogrel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel (600 mg loading dose, 75 mg once daily maintenance dose)
Number of subjects: 0
Study: 21700254

Group type: EXPERIMENTAL
Intervention: Titanium-nitride-oxide (TiNO)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 302
Study: 19812099

Group type: EXPERIMENTAL
Intervention: Clinical pathways (CP) for hospital treatment of HF
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clinical pathways (CP)
Number of subjects: 45
Study: 16333533

Group type: EXPERIMENTAL
Intervention: 10 J/cm2 (2x)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 12 J/cm2 (1x and 2x)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 10 J/cm2 (2x) and 12 J/cm2 (2x)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2x treatment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Residual ablation thickness
Number of subjects: 13
Study: 15584467

Group type: COMPARATOR
Intervention: School-based intervention program designed based on the Attitude, Social Influence and Self-Efficacy model (ASE); implemented in 10 intervention schools.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guided classroom activities, computer tailored messages for children, activities to be completed at home with the family, and family targeted specific actions.
Number of subjects: 0
Study: 11110422

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise training for 2 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both groups (training and control)
Number of subjects: 28
Study: 9352604

Group type: EXPERIMENTAL
Intervention: Injection of rhenium-186
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Injection of rhenium-186 in combination with triamcinolone hexacetonide
Number of subjects: 79

Group type: COMPARATOR
Intervention: Injection of triamcinolone hexacetonide alone
Number of subjects: 79
Study: 8239200

Group type: EXPERIMENTAL
Intervention: Albumin replacement to a level greater than or equal to 3.5 g/dL (AR group)
Number of subjects: 69

Group type: COMPARATOR
Intervention: No albumin replacement (NR group)
Number of subjects: 69
Study: 3884288

Group type: EXPERIMENTAL
Intervention: Conventional chest physiotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mechanical chest vibration
Number of subjects: 20
Study: 28961405

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise at 55% HRmax
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise at 70% HRmax
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intradialytic exercise (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of IDE at 55% vs. 70% HRmax
Number of subjects: 0
Study: 27645318

Group type: EXPERIMENTAL
Intervention: XG/CS
Number of subjects: 148

Group type: COMPARATOR
Intervention: PEG/PG
Number of subjects: 148
Study: 25307414

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY)
Number of subjects: 0
Study: 22172965

Group type: EXPERIMENTAL
Intervention: Optimal CPAP (4cmH(2)O)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham CPAP (4cmH(2)O)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Baseline (no treatment)
Number of subjects: 12
Study: 20668444

Group type: EXPERIMENTAL
Intervention: Noscapine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Glucosamine
Number of subjects: 12
Study: 18979928

Group type: EXPERIMENTAL
Intervention: Patient-selected music
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (nonmusic group)
Number of subjects: 30
Study: 15742449

Group type: EXPERIMENTAL
Intervention: Diclofenac/misoprostol
Number of subjects: 173

Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Patient preference ratings
Number of subjects: 173
Study: 12519045

Group type: EXPERIMENTAL
Intervention: Cesarean section under general anaesthesia (Group 3)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cesarean section with epidural anaesthesia (Group 2)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Vaginal delivery (Group 1)
Number of subjects: 96
Study: 10365287

Group type: EXPERIMENTAL
Intervention: Inogatran (low dose)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Inogatran (medium dose)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Inogatran (high dose)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Inogatran (all doses)
Number of subjects: 320
Study: 7497776

Group type: EXPERIMENTAL
Intervention: Dopexamine (1 mg.kg‐1.min‐1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dopamine (2.5 mg.kg‐1.min‐1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline solution (0.9%)
Number of subjects: 25
Study: 1674295

Group type: EXPERIMENTAL
Intervention: Desferrioxamine (125 mg intramuscularly twice daily, 5 days per week, for 24 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral placebo (lecithin)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 48
Study: 7178257

Group type: EXPERIMENTAL
Intervention: Heat exposure session A (48 degrees C, 34 Torr, 80 min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Heat exposure session B (55 degrees C, 15 Torr, 120 min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Heat exposure session C (48 degrees C, 15 Torr, 180 min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Daily exposures to hot and humid conditions (D: 43 degrees C, 32 Torr, 165 min)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control session (thermoneutral climate: 28 degrees C, 10.5 Torr)
Number of subjects: 7
Study: 31786991

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) training for 6 weeks in a simulation laboratory
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional preparatory materials
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) training
Number of subjects: 24
Study: 28012036

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (3 × 5 min bilateral upper thigh ischemia)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 18
Study: 27140804

Group type: EXPERIMENTAL
Intervention: New presentation of moroctocog alfa (3,000 IU in a dual-chamber syringe)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Combined contents of approved 1,000 and 2,000 IU vials
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both interventions (dual-chamber syringe and combined vials)
Number of subjects: 16
Study: 23861242

Group type: EXPERIMENTAL
Intervention: Hydroxyurea and phlebotomy
Number of subjects: 133

Group type: COMPARATOR
Intervention: Chronic blood transfusion and iron chelation
Number of subjects: 133
Study: 21899583

Group type: EXPERIMENTAL
Intervention: Probiotical (synbiotic food supplement)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 19476175

Group type: EXPERIMENTAL
Intervention: EndoButton femoral fixation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Bone plug placed at the aperture of the femoral tunnel
Number of subjects: 36
Study: 16397875

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Pressure support ventilation plus volume guarantee (PSV + VG)
Number of subjects: 25
Study: 15134183

Group type: EXPERIMENTAL
Intervention: Indinavir 600 mg + Ritonavir 100 mg twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Indinavir 400 mg + Ritonavir 100 mg twice daily
Number of subjects: 16
Study: 11487446

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 0
Study: 9254875

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections (monophasic in 9 patients, biphasic in 5 patients)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections (biphasic)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combined functional score from physicians, therapists, and parents
Number of subjects: 14
Study: 8015885

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (50 mg, 3.7 +/- 0.9 mg/kg)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Acetaminophen (100 mg, 7.7 +/- 1.7 mg/kg)
Number of subjects: 79